Accelerate Diagnostics, Inc. (0H8E.L)

USD 1.48

(-6.88%)

Market Cap (In USD)

30.05 Million

Revenue (In USD)

12.05 Million

Net Income (In USD)

-61.61 Million

Avg. Volume

995.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.47679-7.0822
PE
-
EPS
-
Beta Value
0.598
ISIN
US00430H2013
CUSIP
00430H201
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Specialties
CEO
Mr. Jack Phillips
Employee Count
-
Website
https://acceleratediagnostics.com
Ipo Date
2018-01-29
Details
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.